Charts Week Month
Heat map Market Overview
Sentiment Sectors ETFs
Earnings News Earnings Movers The Drift Pivots SEC Filings
The Big Picture Breakouts Full Earnings News
Investor Services

Earnings are the driver of stock prices and the right earnings information can help longer-term investors significantly outperform the overall stock market.

The Whisper Report ® A look at upcoming earnings from both a top-down and bottom-up basis. Grades Stocks with A+ Earnings Whisper Grades Have Significantly Outperformed the Stock Market. Call Summaries Conference call summaries. AI Call Analysis AI Conference call analysis. Earnings Daily earnings results. Guidance Daily earnings guidance from companies. Reactions Earnings Screener Short Interest Report When the short trade becomes crowded.
Trader Service

Short-term earnings trading tools built around expectations, sentiment, quantitative studies, volatility, and post-earnings drift.

Trading Strategy The current strategy based on a broad market analysis and data. Earnings Whisper Plays Combining research, sentiment, quantitative studies, and technical analysis for short-term trades. Scores Identifying the likely Earnings Announcement Premium. Power Ratings Earnings with enough power for a short-term Post-Earnings Announcement Drift. Whisperings ^TM Whisperings are comments from analysts about upcoming earnings releases. AI Call Rankings Find which companies had the strongest or weakest conference calls. Option Trades Volatility Options Activity Unusual options activity around earnings. Trends Where price, fundamentals and sentiment are pointing. Setups Unusual options activity around earnings. Reversals Unusual options activity around earnings. Spikes Unusual options activity around earnings.
Dashboard

EYPT EyePoint, Inc.

NASDAQ

$4.58

EyePoint, Inc. (EYPT) Earnings News

Earnings press releases and Earnings Whispers previews for EyePoint, Inc. (EYPT), newest first.

Monday August 17, 2026 7:00 AM ET

EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD

Wednesday August 5, 2026 7:00 AM ET

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

Thursday July 30, 2026 7:00 AM ET

EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)

Monday July 13, 2026 7:00 AM ET

EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer

Thursday May 14, 2026 7:00 AM ET

EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data

Wednesday May 6, 2026 7:00 AM ET

EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments

Wednesday April 29, 2026 7:00 AM ET

EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026